Busulfan - Warnings and Precautions

WARNINGS The most frequent, serious side effect of treatment with busulfan is the induction of bone marrow failure (which may or may not be anatomically hypoplastic) resulting in severe pancytopenia.

The pancytopenia caused by busulfan may be more prolonged than that induced with other alkylating agents.

It is generally felt that the usual cause of busulfan-induced pancytopenia is the failure to stop administration of the drug soon enough; individual idiosyncrasy to the drug does not seem to be an important factor.

MYLERAN should be used with extreme caution and exceptional vigilance in patients whose bone marrow reserve may have been compromised by prior irradiation or chemotherapy, or whose marrow function is recovering from previous cytotoxic therapy.

Although recovery from busulfan-induced pancytopenia may take from 1 month to 2 years, this complication is potentially reversible, and the patient should be vigorously supported through any period of severe pancytopenia.

A rare, important complication of busulfan therapy is the development of bronchopulmonary dysplasia with pulmonary fibrosis.

Symptoms have been reported to occur within 8 months to 10 years after initiation of therapy—the average duration of therapy being 4 years.

The histologic findings associated with “busulfan lung” mimic those seen following pulmonary irradiation.

Clinically, patients have reported the insidious onset of cough, dyspnea, and low-grade fever.

In some cases, however, onset of symptoms may be acute.

Pulmonary function studies have revealed diminished diffusion capacity and decreased pulmonary compliance.

It is important to exclude more common conditions (such as opportunistic infections or leukemic infiltration of the lungs) with appropriate diagnostic techniques.

If measures such as sputum cultures, virologic studies, and exfoliative cytology fail to establish an etiology for the pulmonary infiltrates, lung biopsy may be necessary to establish the diagnosis.

Treatment of established busulfan-induced pulmonary fibrosis is unsatisfactory; in most cases the patients have died within 6 months after the diagnosis was established.

There is no specific therapy for this complication.

MYLERAN should be discontinued if this lung toxicity develops.

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful.

Busulfan may cause cellular dysplasia in many organs in addition to the lung.

Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow.

This cytologic dysplasia may be severe enough to cause difficulty in interpretation of exfoliative cytologic examinations from the lung, bladder, breast, and the uterine cervix.

In addition to the widespread epithelial dysplasia that has been observed during busulfan therapy, chromosome aberrations have been reported in cells from patients receiving busulfan.

Busulfan is mutagenic in mice and, possibly, in humans.

Malignant tumors and acute leukemias have been reported in patients who have received busulfan therapy, and this drug may be a human carcinogen.

The World Health Organization has concluded that there is a causal relationship between busulfan exposure and the development of secondary malignancies.

Four cases of acute leukemia occurred among 243 patients treated with busulfan as adjuvant chemotherapy following surgical resection of bronchogenic carcinoma.